Irradiation-induced angiogenesis is associated with an MMP-9-miR-494- syndecan-1 regulatory loop in medulloblastoma cells

Oncogene

Volumn 33, Issue 15, 2014, Pages 1922-1933

  Asuthkar, S ^a   Velpula, K K ^a   Nalla, A K ^a   Gogineni, V R ^a   Gondi, C S ^a   Rao, J S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

3 untranslated region (30 UTR); CpG methylation; ionizing radiation (IR); matrix metalloproteinase 9 (MMP 9); microRNA 494 (miR 494); syndecan 1 (SDC1)

Indexed keywords

ADOLESCENT; ANIMALS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MATRIX METALLOPROTEINASE 9; MEDULLOBLASTOMA; MICE; MICE, NUDE; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; RADIATION, IONIZING; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SYNDECAN-1;

EID: 84899448152     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.151     Document Type: Article

References (59)

1. Taillandier L, Blonski M, Carrie C, Bernier V, Bonnetain F, Bourdeaut F, et al. [Medulloblastomas: Review]. Rev Neurol (Paris) 2011; 167: 431-448
2. Massimino M, Cefalo G, Riva D, Biassoni V, Spreafico F, Pecori E, et al. Long-Term results of combined preradiation chemotherapy and age-Tailored radiotherapy doses for childhood medulloblastoma. J Neurooncol 2012; 108: 163-171
3. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5: 429-441
4. Brieger J, Schroeder P, Gosepath J, Mann WJ. The cyclooxygenase inhibitor flurbiprofen reduces radiation-induced angiogenic growth factor secretion of squamous cell carcinoma cell lines. Ann NY Acad Sci 2004; 1030: 37-42
5. Artacho-Cordon F, Rios-Arrabal S, Lara PC, Artacho-Cordon A, Calvente I, Nunez MI. Matrix metalloproteinases: Potential therapy to prevent the development of second malignancies after breast radiotherapy. Surg Oncol 2012; 21: E143-e151
6. Bergers G, Hanahan D. Modes of resistance to anti-Angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603
7. Asuthkar S, Nalla AK, Gondi CS, Dinh DH, Gujrati M, Mohanam S, et al. Gadd45a sensitizes medulloblastoma cells to irradiation and suppresses MMP-9-mediated EMT. Neuro Oncol 2011; 13: 1059-1073
8. Oh JH, Lee HS, Park SH, Ryu HS, Min CK. Syndecan-1 overexpression promotes tumor growth and angiogenesis in an endometrial cancer xenograft model. Int J Gynecol Cancer 2010; 20: 751-756
9. Ibrahim SA, Yip GW, Stock C, Pan JW, Neubauer C, Poeter M, et al. Targeting of syndecan-1 by microRNA miR-10b promotes breast cancer cell motility and invasiveness via a Rho-GTPase-And E-cadherin-dependent mechanism. Int J Cancer 2012; 131: E884-E896
10. Yang Y, Macleod V, Miao HQ, Theus A, Zhan F, Shaughnessy Jr JD, et al. Heparanase enhances syndecan-1 shedding: A novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem 2007; 282: 13326-13333
11. Khotskaya YB, Dai Y, Ritchie JP, Macleod V, Yang Y, Zinn K, et al. Syndecan-1 is required for robust growth, vascularization, and metastasis of myeloma tumors in vivo. J Biol Chem 2009; 284: 26085-26095
12. Oh JH, Kim JH, Ahn HJ, Yoon JH, Yoo SC, Choi DS, et al. Syndecan-1 enhances the endometrial cancer invasion by modulating matrix metalloproteinase-9 expression through nuclear factor kappaB. Gynecol Oncol 2009; 114: 509-515
13. Brule S, Charnaux N, Sutton A, Ledoux D, Chaigneau T, Saffar L, et al. The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9. Glycobiology 2006; 16: 488-501
14. Endo K, Takino T, Miyamori H, Kinsen H, Yoshizaki T, Furukawa M, et al. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J Biol Chem 2003; 278: 40764-40770
15. Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002; 111: 635-646
16. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297
17. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355
18. Li X, Luo F, Li Q, Xu M, Feng D, Zhang G, et al. Identification of new aberrantly expressed miRNAs in intestinal-Type gastric cancer and its clinical significance. Oncol Rep 2011; 26: 1431-1439
19. Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav D, An F, Popescu I, et al. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 2011; 54: 2089-2098
20. Kim WK, Park M, Kim YK, Tae YK, Yang HK, Lee JM, et al. MicroRNA-494 downregulates KIT and inhibits gastrointestinal stromal tumor cell proliferation. Clin Cancer Res 2011; 17: 7584-7594
21. Nikolova V, Koo CY, Ibrahim SA, Wang Z, Spillmann D, Dreier R, et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 2009; 30: 397-407
22. Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC, et al. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood 2010; 115: 2449-2457
23. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 2008; 283: 32628-32636
24. Seidel C, Borset M, Hjertner O, Cao D, Abildgaard N, Hjorth-Hansen H, et al. High levels of soluble syndecan-1 in myeloma-derived bone marrow: Modulation of hepatocyte growth factor activity. Blood 2000; 96: 3139-3146
25. Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS. MicroRNA targets in Drosophila. Genome Biol 2003; 5: R1
26. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. Nat Genet 2007; 39: 1278-1284
27. Floer M, Gotte M, Wild MK, Heidemann J, Gassar ES, Domschke W, et al. Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice. Am J Pathol 2010; 176: 146-157
28. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-A mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-116
29. Li LC, Dahiya R. MethPrimer: Designing primers for methylation PCRs. Bioinformatics 2002; 18: 1427-1431
30. Purushothaman A, Hurst DR, Pisano C, Mizumoto S, Sugahara K, Sanderson RD. Heparanase-mediated loss of nuclear syndecan-1 enhances histone acetyltransferase (HAT) activity to promote expression of genes that drive an aggressive tumor phenotype. J Biol Chem 2011; 286: 30377-30383
31. Balasubramanyam K, Swaminathan V, Ranganathan A, Kundu TK. Small molecule modulators of histone acetyltransferase p300. J Biol Chem 2003; 278: 19134-19140
32. Kishikawa S, Ugai H, Murata T, Yokoyama KK. Roles of histone acetylation in the Dnmt1 gene expression. Nucleic Acids Res Suppl 2002 209-210
33. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163-176
34. Jalkanen M, Rapraeger A, Saunders S, Bernfield M. Cell surface proteoglycan of mouse mammary epithelial cells is shed by cleavage of its matrix-binding ectodomain from its membrane-Associated domain. J Cell Biol 1987; 105: 3087-3096
35. Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-777
36. Ezhilarasan R, Jadhav U, Mohanam I, Rao JS, Gujrati M, Mohanam S. The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int J Cancer 2009; 124: 306-315
37. Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009; 137: 1005-1017
38. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838
39. Zhang Z, Zhang B, Li W, Fu L, Fu L, Zhu Z, et al. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer 2011; 2: 782-791
40. Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson AD, et al. Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 2004; 25: 661-668
41. Zhao C, Bu X, Zhang N, Wang W. Downregulation of SFRP5 expression and its inverse correlation with those of MMP-7 and MT1-MMP in gastric cancer. BMC Cancer 2009; 9: 224
42. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22: 4632-4642
43. Han L, Witmer PD, Casey E, Valle D, Sukumar S. DNA methylation regulates MicroRNA expression. Cancer Biol Ther 2007; 6: 1284-1288
44. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-1992
45. Fang JY, Lu YY. Effects of histone acetylation and DNA methylation on p21( WAF1) regulation. World J Gastroenterol 2002; 8: 400-405
46. Fandy TE, Gore SD. Epigenetic targets in human neoplasms. Epigenomics 2010; 2: 221-232
47. Sung B, Pandey MK, Ahn KS, Yi T, Chaturvedi MM, Liu M, et al. Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis. Blood 2008; 111: 4880-4891
48. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NFkappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008; 111: 2364-2373
49. Huang YC, Hung WC, Chen WT, Yu HS, Chai CY. Effects of DNMT and MEK inhibitors on the expression of RECK, MMP-9,-2, uPA and VEGF in response to arsenite stimulation in human uroepithelial cells. Toxicol Lett 2011; 201 62-71
50. Bigner SH, Friedman HS, Vogelstein B, Oakes WJ, Bigner DD. Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 1990; 50: 2347-2350
51. Ali-Osman F, Stein DE, Renwick A. Glutathione content and glutathione-S-Transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea- resistant human malignant astrocytoma cell lines. Cancer Res 1990; 50: 6976-6980
52. Bhoopathi P, Chetty C, Dontula R, Gujrati M, Dinh DH, Rao JS, et al. SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1/STAT3 pathway. Cancer Res 2011; 71: 4908-4919
53. Kunigal S, Lakka SS, Gondi CS, Estes N, Rao JS. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer 2007; 121: 2307-2316
54. Lindsey JC, Lusher ME, Anderton JA, Gilbertson RJ, Ellison DW, Clifford SC. Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma. Br J Cancer 2007; 97: 267-274
55. Asuthkar S, Gondi CS, Nalla AK, Velpula KK, Gorantla B, Rao JS. Urokinase-Type plasminogen activator receptor (uPAR)-mediated regulation of WNT/beta-catenin signaling is enhanced in irradiated medulloblastoma cells. J Biol Chem 2012; 287: 20576-20589
56. Gondi CS, Lakka SS, Dinh DH, Olivero WC, Gujrati M, Rao JS. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. Oncogene 2004; 23: 8486-8496
57. Levasseur JE, Wei EP, Raper AJ, Kontos AA, Patterson JL. Detailed description of a cranial window technique for acute and chronic experiments. Stroke 1975; 6: 308-317
58. Shan S, Lockhart AC, Saito WY, Knapp AM, Laderoute KR, Dewhirst MW. The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats. Clin Cancer Res 2001; 7: 2590-2596
59. Semenza GL. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 2002; 8: S62-S67